

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
18025-1013SERIAL NO.  
09/887,281LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
Banerjee *et al.*FILING DATE  
June 22, 2001GROUP  
1614

## U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	A	3	9	9	4	9	7	4	11/30/76	Murakami et al	260	562	05/07/74
	B	5	0	3	3	2	5	2	07/23/91	Carter	53	425	07/30/90
	C	5	0	5	2	5	5	8	10/01/91	Carter	206	439	07/27/90
	D	5	3	2	3	9	0	7	06/28/94	Kalvelage	206	531	03/15/93
	E	5	5	2	5	6	2	3	06/11/96	Spear et al	514	423	03/11/94
	F	5	6	0	2	1	1	0	02/11/97	Drumm et al	514	47	01/26/95
	G	5	6	5	4	2	7	6	08/05/97	Barrett et al	514	13	06/07/95
	H	5	6	6	8	1	1	0	09/16/97	Barrett et al	514	13	06/07/95
	I	5	6	7	4	8	6	0	10/07/97	Carling et al	514	171	10/03/94
	J	5	6	7	7	2	8	0	10/14/97	Barrett et al	514	14	06/07/95
	K	5	6	7	7	8	0	9	10/14/97	Kadlec	360	78.09	06/01/95
	L	5	6	8	3	9	8	3	11/04/97	Barrett et al	514	12	06/07/95
	M	5	6	9	1	3	3	6	11/25/97	Dorn et al	514	236.2	09/08/95
	N	5	7	3	3	5	2	6	03/31/98	Trevino et al	424	9.52	12/14/95
	O	5	7	5	0	5	4	9	05/12/98	Caldwell et al	514	364	10/15/96
	P	5	7	8	0	4	6	7	07/14/98	Dorn et al	514	236.2	08/08/97
	Q	5	7	9	5	5	6	4	08/18/98	Aberg et al	424	45	03/07/96
	R	5	8	7	4	4	8	1	02/23/99	Weers et al	514	761	06/07/95
	S	5	8	7	7	1	9	1	03/02/99	Caldwell et al	514	337	10/22/97
	T	5	9	2	9	0	9	4	07/27/99	Durette et al	514	340	10/22/97
	U	5	9	6	5	6	2	2	10/12/99	Senanayake	514	653	06/23/98
	V	5	9	7	2	9	1	9	10/26/99	Carling et al	514	171	10/07/97
	W	6	0	0	4	5	3	7	12/21/99	Blondino et al	424	45	12/18/98
	X	6	0	4	0	3	4	4	03/21/00	Gao et al	514	554	05/21/98

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
18025-1013SERIAL NO.  
09/887,281LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
Banerjee *et al.*FILING DATE  
June 22, 2001GROUP  
1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	Y	6	0	4	1	7	7	7	03/28/00	Faithfull et al	128	200.24	12/01/95
	Z	6	0	6	8	8	3	3	05/30/00	Aberg et al	424	45	08/18/98
	AA	6	0	7	1	9	7	1	06/06/00	Senanayake	514	653	05/05/99
	AB	6	1	2	6	9	1	9	10/03/00	Stefely et al	424	45	02/07/97
	AC	6	1	3	6	6	0	3	10/24/00	Dean et al	435	375	03/26/99
	AD	6	1	5	0	4	1	8	11/21/00	Hochrainer et al	514	630	11/12/99
	AE	6	1	6	1	5	3	6	12/19/00	Redmon et al	128	200.14	10/07/98

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
	AF	2	3	0	5	0	9	2	02/02/73	Germany				
	AG	9	9	0	0	1	3	4	07/01/99	PCT				
	AH	9	9	3	6	0	9	5	22/07/99	PCT				

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AI	Bartow and Brogden, "An Update of its Pharmacological Properties and Therapeutic Efficacy in the Management of Asthma," <i>Drugs</i> , <u>55(2)</u> :303-322 (1998)
AJ	Campbell <i>et al</i> , "A comparison of the efficacy of long-acting B2-agonists: eformoterol via Turbuhaler(R) and salmeterol via pressurized metered dose inhaler or Accuhaler (R), in mild to moderate asthmatics," <i>Respiratory Medicine</i> , <u>93</u> :236-244 (1999)
AK	Dellamary <i>et al</i> , "Hollow Porous Particles in Metered Dose Inhalers," <i>Pharmaceutical Research</i> , <u>17(2)</u> :168-174 (2000)
AL	Derwent# 000971705, WPI Acc. No. 1973-48969U/197335 citing German Patent Application No. DE 2305092 A, "Alpha-aminomethylbenzyl alcohol derivs. -prepd. by redn. of corresponding protected derivs."
AM	Ekstrom <i>et al</i> , "Low-dose formoterol Turbuhaler(R) (Oxis(R)) b.i.d., a 3-month placebo-controlled comparison with terbutaline (q.i.d.)," <i>Respiratory Medicine</i> , <u>92</u> :1040-1045 (1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
18025-1013SERIAL NO.  
09/887,281LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
Banerjee *et al.*FILING DATE  
June 22, 2001GROUP  
1614

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AN	Kaumann and Lemoine, "Direct labelling of myocardial B1-adrenoceptors; Comparison of binding affinity of 3H-(--)-bisoprolol with its blocking potency," <i>Archives of Pharmacology</i> , <u>331</u> :27-39 (1985)
AO	Lecaillon <i>et al.</i> , "Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder Inhalation via aerolizer (TM)," <i>European Journal Clinical Pharmacology</i> , <u>55</u> :131-138 (1999)
AP	Lemoine <i>et al.</i> , "Direct labelling of B2-adrenoceptors; Comparison of binding potency of 3H-ICI 118,551 and blocking potency of ICI 118,551," <i>Archives of Pharmacology</i> , <u>331</u> :40-51 (1985)
AQ	Lotvall <i>et al.</i> , "Similar bronchodilation with formoterol delivered by Aerolizer or Turbuhaler," <i>Can Respir J</i> , <u>6</u> (5):412-416 (1999)
AR	Nielsen <i>et al.</i> , "Flow-dependent effect of formoterol dry-powder inhaled from the Aeolizer (R)," <i>Eur Respir J</i> , <u>10</u> :2105-2109 (1997)
AS	Nightingale <i>et al.</i> , "Differential Effect of Formoterol on Adenosine Monophosphate and Histamine Reactivity in Asthma," <i>Am J Respir Crit Care Med</i> , <u>159</u> :1786-1790 (1999)
AT	Nogrady, T., (editor), <i>Medicinal Chemistry: A Biochemical Approach</i> , Oxford University Press, New York, pgs. 388-392 (1985)
AU	Palmqvist <i>et al.</i> , "Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency," <i>Eur Respir J</i> , <u>10</u> :2484-2489 (1997)
AV	Rico-Mendez <i>et al.</i> , "Formoterol en polvo seco, dos veces al día versus salbutamol aerosol, cuatro veces al día, en pacientes con asma estable," <i>Revista Alergia Mexico</i> , <u>XLVI</u> (5):130-135 (1999)
AX	Ringdal <i>et al.</i> , "Onset and duration of action of single doses of formoterol inhaled via Turbuhaler(R)," <i>Respiratory Medicine</i> , <u>92</u> :1017-1021 (1998)
AY	Schreurs <i>et al.</i> , "A dose-response study with formoterol Turbuhaler(R) as maintenance therapy in asthmatic patients," <i>Eur Respir J</i> , <u>9</u> :1678-1683 (1996)
AZ	Seberova and Andersson, "Oxis(R) (formoterol given by Turbuhaler(R)) showed as rapid an onset of action as salbutamol given by a pMDI," <i>Respiratory Medicine</i> , <u>94</u> :607-611 (2000)
BA	Selroos <i>et al.</i> , "Delivery Devices for Inhaled Asthma Medication," <i>Clin Immunother</i> , <u>6</u> :273-299 (1996)
BB	Tomioka <i>et al.</i> , "Anti-Allergic Activities of the B-Adrenoceptor Stimulant Formoterol (BD 40A)," <i>Arch Int Pharmacodyn</i> , <u>250</u> :279-292 (1981)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
18025-1013SERIAL NO.  
09/887,281LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
Banerjee *et al.*FILING DATE  
June 22, 2001GROUP  
1614

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

BC	Totterman <i>et al</i> , "Tolerability to high doses of formoterol and terbutaline via Turbuhaler(R) for 3 days in stable asthmatic patients," <i>Eur Respir J</i> , <u>12</u> :573-579 (1998)
BD	Ullman <i>et al</i> , "Formoterol inhaled as dry powder or via pressurized metered-dose inhaler in a cumulative dose-response study," <i>Allergy</i> , <u>51</u> :745-748 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.